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Abstract
Background: Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor prognosis, which frequently
exhibits HER-2 gene amplification. Trastuzumab, the humanized antibody against HER-2, has potent growth inhibitory
effects on HER-2 overexpressing cancers. One effect of trastuzumab is that it causes HER-2 receptor internalization and
degradation, enhancing presentation of HER-2 epitopes on MHC-Class I molecules. This enhances the ability of HER-2
specific cytotoxic T lymphocytes (CTLs) to recognize and kill cancer cells. Novel strategies targeting the HER-2 receptor
either directly by trastuzumab and/or indirectly by inducing a CTL response against HER-2 epitopes with, for instance, DC
immunotherapy and consequently combining these strategies might prove to be very effective.
Methodology/Principal Findings: In this study we report that trastuzumab has potent growth inhibitory effects on two
HER-2 overexpressing EAC cell lines OE33 and OE19. However, we found that trastuzumab and HER-2 specific CTLs act
synergistically in inducing tumor lysis in OE33 but not in OE19. We discovered that in OE19 this deficient response is due to
a down-regulation of the Transporter Associated with Antigen Processing-2 (TAP-2). TAP-2 is an important member of the
Antigen Processing Machinery (APM), and is one of the essential elements for loading antigens on MHC class I molecules.
Importantly, we demonstrated that by inducing re-expression of TAP-2 in OE19 with INF-c treatment or by incubating the
cells with INF-c producing CTLs, the specific anti HER-2 CTL tumor lysis response and synergistic effect with trastuzumab can
be restored.
Conclusion: An inefficient response of HER-2 overexpressing EAC to trastuzumab and/or DC immunotherapy can be due to
a down-regulated TAP-2 expression and thus a deficient APM. Future studies combining trastuzumab with IFN-c and/or
immune-therapies inducing potent anti HER-2 CTL responses could lead to an effective combinatorial strategy for successful
treatment of HER-2 overexpressing but APM defective cancers.
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Introduction
HER-2/neu is a 185 KDa transmembrane glycoprotein with
tyrosine kinase activity[1]. It is overexpressed, mostly via gene
amplification, in several aggressive cancers [2], such as in 25–30%
of ovarian and breast cancers [3,4], 35–45% of pancreatic
carcinomas [5], and in 30–80% of EAC [6–9]. Interestingly,
cytotoxic T-lymphocyte (CTL) responses against several HER-2
peptides have been observed in cancer patients, indicating that the
HER-2/neu protein is immunogenic. Therefore, the HER-2/neu
receptor is regarded as an ideal Tumor Associated Antigen, which
might be employed for anti-cancer immunotherapy [10,11,12].
Moreover, targeting of the HER-2 receptor by the humanized
antibody trastuzumab has been shown to result in potent growth
inhibition of HER-2 overexpressing tumors [13,14]. In clinical
studies trastuzumab has been shown to give significant results,
particularly in the treatment of breast cancer [15,16]. Applying
trastuzumab as an additional treatment option is an attractive
strategy for tumors with poor prognosis bearing HER-2 overex-
pression, such as EAC. In Western countries, this cancer has the
most rapidly increasing incidence compared to other cancers
[17,18]. Currently, the main treatment for this disease is surgical
resection, yet, even after surgery with or without neo-adjuvant or
adjuvant chemo- and radiotherapy, the median survival of these
patients is less than 2 years [19,20]. Recently, several studies suggest
that therapies targeting HER-2 either by specific anti-HER-2
antibodies or induced anti-HER-2 CTLs or a combination of these
treatments may be effective (neo) adjuvant treatments for HER-2
positive cancers [13,14]. At present, only a few reports have
explored the possibility of applying trastuzumab as an additional
treatment option for EAC patients in phase I/II studies. Results
from this study are still pending, however in the initial phase the
treatment induced an overall toxicity, which was not increased as
compared to previous studies using this antibody [21].
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12424The underlying mechanisms of action of trastuzumab are
diverse and not yet fully understood. One recognized effect of
trastuzumab is the enhancement of the immune system response
such as Antibody Dependent Cellular Cytotoxicity (ADCC)
[22,23]. Yet, another lesser known, but crucial effect of
trastuzumab is the enhancement of the MHC-Class I restricted
HER-2 epitope presentation on tumor cells. This results in a
boosted HER-2 specific CTL response and, consequently,
increased tumor cell lysis. In this regard, it has been previously
shown that HER-2 overexpressing gastric cell lines and esophageal
squamous cancer cells treated with trastuzumab are sensitized and
more susceptible to killing by HER-2 specific CTLs [24,25].
We previously demonstrated in an ex-vivo model that DC
mediated CTL responses could be an advantageous approach for
improving EAC treatment [26]. Both DC immunotherapy and the
use of trastuzumab in the clinic has resulted so far in partly
improved patient responses, however, these were undeniably
below expectations.
In this study, we questioned whether DC mediated anti HER-2
specific CTL immunotherapy combined with trastuzumab could
be an even more effective strategy for treatment of EAC. To this
aim, we firstly examined the level of gene amplification and
protein overexpression in EAC cell lines by Fluorescence In Situ
Hybridization (FISH) and immunocytochemistry (ICC). We then
evaluated the effect of trastuzumab on HER-2 overexpressing
EAC cell lines. Furthermore, we studied whether trastuzumab
sensitizes HER-2 overexpressing tumor cells to lysis by HER-2
specific CTLs. Remarkably, in one of the HER-2 positive EAC
cell lines OE33 we observed a synergy between trastuzumab
treatment and specific anti-HER-2 CTL responses. However, the
other EAC cell line OE19, was not sensitive to HER-2 specific
CTLs also without trastuzumab pre-treatment. Investigation of the
status of several components of the Antigen Processing Machinery
(APM) in this cell line and in EAC tumor biopsy specimens showed
that the expression of one of the most important components of
the APM, the Transporter Associated with Antigen Processing-2
(TAP-2) is specifically down regulated in OE19 and also in a high
percentage of EAC. Importantly, we show that TAP-2 can be re-
induced not only by IFN-c treatment, but also by potent IFN-c
producing CTL populations. Importantly, up-regulation of TAP-2
restored the synergistic cytotoxic effect of trastuzumab and the anti
HER-2 CTL response in OE19. We further show that the HER-2
specific CTLs induced cytotoxicity, in synergy with trastuzumab,
specifically depends on an intact APM, in view of the fact that
down-regulation of TAP-2 expression in the TAP-2 proficient cell
line OE33 hinders the synergistic cytotoxic effect induced by
CTLs and trastuzumab. In the future, it will be of importance to
assess the levels of TAP-2 expression in EAC patient in order to
improve clinical responses to DC immunotherapy and trastuzu-
mab or combinatorial targeted therapies.
Materials and Methods
Cell Lines
EAC cell lines OE19 and OE33 were obtained from ECACC
(Porton Down, Wiltshire, SP4 DJG, UK), SW620, a colorectal
adenocarcinoma cell line used as control [27], was a kind gift from
Dr. David Beer (University of Washington, USA). OE19 and
OE33 were maintained in RPMI 1640 medium with addition of
L-glutamine, antibiotics and Fetal Calf Serum (FCS). SW620 was
kept in DMEM medium with addition of L-glutamine, antibiotics
and FCS. All the cell lines were cultured at 37uCa t5 %C O 2 and
medium was refreshed every three days. The HLA-A2 status of the
cell lines was determined by FACS analysis using an anti-human
HLA-A2 antibody FITC conjugated (BD, The Netherlands). The
FACS Staining procedure was performed as described previously
[26].
Biopsy specimens from EAC patients
The study was approved by the Academic Medical Center
Hospital’s Medical Ethical Committee, Amsterdam, The Nether-
lands. After informed consent and written permission, sixteen
patients were included. Patients underwent endoscopic procedures
for classifying, staging and grading of the esophageal cancer.
During this procedure, 3 extra biopsies of each patient were taken
to be used for experimental purposes; biopsies were obtained from
both normal squamous epithelium taken at least 3 cm above the
malignant mass, and from the malignancy itself. Matching biopsies
from the same spots were taken for histopathological diagnosis.
Biopsies were collected in Trizol and RNA was extracted as
previously described [26].
Fluorescent in situ hybridization (FISH)
Upon reaching a confluence of 70–80%, EAC cell lines OE33,
OE19 and SW620 were trypsinized, spun down and collected in
PBS. A Cytospin (Shandon Cytospin 4 Cytocentrifuge, Thermo,
Waltham, MA) was used to generate a single layer of cells on a
glass slide as described before (45). We used directly labeled
fluorescent chromosomal centromeric probes (CEP) for chromo-
some 17 and 17q11.2- q12 (Her-2/neu), obtained from Vysis
(Downers Grove, IL). DNA-FISH was performed according to the
manufacturer’s instructions provided by Vysis as described before
by our group [28].
Fluorescent immuno-cytochemistry
Cultured EAC cells were plated in a 24 well plate at a
concentration of 2, 5610
4/ml and grown on coverslips. After
24 hours, cultured cells were fixed directly in the well for 20
minutes in Phosphate Buffered Saline (PBS) with 4% Paraformal-
dehyde (PFA) and 0.1% Triton X-100 and then washed in PBS.
Blocking of aspecific antigens was performed by incubating slides
for 45 minutes with PBS containing 1% BSA and 10% Fetal Calf
Serum (FCS). Slides were washed with PBS and incubated
overnight at 4uC with the appropriately diluted primary HER-2
antibody, c-erbB-2/HER-2/neuAb-17 (Lab Vision Corporation,
Freemont, CA, USA) in PBS with 1% BSA and 0.1% Triton X-
100. After washing with PBS, cells were incubated with a mouse
anti-human secondary FITC conjugated antibody (Dako, Den-
mark) diluted 1:500 in PBS. Cells attached on coverslips were
placed on Superfrost + (Menzel Glaser, Braunschweig, Germany)
glass slides and mounted with DAPI (Roche, Mannheim,
Germany)/vectashield (Vector laboratories Inc, Burlingame, CA,
USA).
Generation of HER-2 mRNA by in vitro transcription (IVT)
HER-2 mRNA was made as previously described [29]. Briefly,
to generate HER-2 mRNA, plasmid pSPJC1 with an insert coding
for HER-2 (a gift from Prof. A. Ulrich, Martinsried, Germany) was
used. This plasmid allows in vitro transcription under the control
of an SP6 promoter. The plasmid was linearized using NdeI (MBI
Fermentas, St. Leon-Rot, Germany) and in vitro transcription was
subsequently performed using Ambion in vitro transcription kit
with an SP6 promoter (Ambion, Nieuwerkerk a/d, IJssel, The
Netherlands), and the manufacturer’s procedure was followed.
The in vitro transcribed mRNA was purified using RNeasy Midi
Kit (Qiagen, Hilden, Germany) according to the manufacture’s
instructions. The RNA was then dissolved in RNase-free H2O and
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the NanodropH according to the manufacturer’s instructions.
(Nanodrop Tecnologies, type ND-1000, Wilmington, USA).
Maturation of HER-2 mRNA loaded Dendritic Cells and
Induction of anti HER-2 specific CTLs
HLA-A2 matching monocytes obtained from a buffy coat and
characterized as CD14+, CD832, CD862, CD2092 were used
for electroporation with HER-2 mRNA. The electroporation
procedure and the isolation of monocytes and maturation of DCs
were performed as previously described [30]. The electroporation
efficacy of HER-2 mRNA was assessed through measuring HER-2
expression by FACS analysis. FACS staining was performed as
described before [26]. A mouse anti-human HER-2 primary
monoclonal antibody, clone 9G6.10 (Lab Vision, Fremont, CA),
an anti-mouse PE conjugated antibody, and an isotype control for
the anti-mouse PE secondary antibody were used. Expression was
measured in monocytes 24 hours after electroporation (day one)
and eight days after electroporation.
The obtained HER-2 loaded mature DCs were twice co-
incubated for seven days with autologous lymphocytes in a ratio of
1:4 (5610
5 DCs and 2610
6 lymphocytes) in 24 well plates in AIM
V medium with 2% penicillin-streptomycin (GIBCO) without
FCS. To obtain a control population, lymphocytes were also
incubated with mock transfected DCs.
Mixed Leucocyte Reaction (MLR) and [
3H] thymidine
incorporation assay
Mature DCs electroporated with HER-2 RNA and mock DCs
were co-cultured in flat-bottom 96-well plates (Nunc, Roskilde,
Denmark) with lymphocytes in IMDM medium at different target-
effector ratios, starting from 4610
3/well, down to 1.25610
2 DCs
per well, while each well contained a fixed number of 5610
4
lymphocytes. After 5 days in culture, 0.2 mCi [
3H] thymidine
(Amersham Biosciences, Amersham, UK) was added to each well
and the incorporation of radioactivity was measured after
16 hours using liquid scintillation counting.
MTT assay
OE33, OE19 and SW620 cells were treated with several
concentrations of trastuzumab, namely 2.5, 5 and 10 mg/ml, or
left untreated for control purposes. Cells were treated for 24 hours
or 72 hours, transferred on an enzymatic 96 wells plate and co-
incubated with MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide], for 4 hours. Ethanol absolute (96%) was
added to stop the reaction, and results were read on a multi-well
scanning spectrophotometer (ELISA reader).
Apoptosis assay
Each cell line (1610
4 cells) was cultured in 2 ml of RPMI 1640
and DMEM as appropriate with or without trastuzumab (10 mg/
mL) at 37uC for 48 hours in a six-well plate. After incubation, cells
were harvested, spun down, and stained for FACS analysis as
described previously [26]. Apoptosis of the trastuzumab treated
versus non treated cells was measured by using the following
antibodies: anti-human Annexin-V APC conjugated (ICQ,
Groningen, The Netherlands), in order to quantify apoptosis;
Via-probe 7aad (necrosis marker; R&D System), in order to
exclude necrotic cells from the final analysis. Data were acquired
using BD Cell Quest Pro Software. Apoptotic epithelial cells were
gated as positive for AnnexinV and negative for 7aad and as
positive when compared to the isotype control antibody for
Annexin V.
Cytotoxicity assay
The HLA-A2 positive/HER-2 positive OE33 and OE19 cell
lines and the HLA-A2 positive/HER-2 negative SW620 cell line
were pre-incubated for 48 hours with 10 mg/ml trastuzumab.
Hereupon, 1610
4 treated and non treated cells (target) were co-
incubated with effector cells i.e., the HLA matched HER-2 specific
CTLs or non specific CTLs (lymphocytes stimulated with mock
transfected DCs), at various E:T ratios, namely 5:1, 2.5:1, 1.25:1
and 0.62:1, in 100 ml of RPMI 1640 in a 96-well plates in triplicate
for 4 hours at 37uC.
The percentage of cytotoxicity was measured by the CytoTox
96 Non-Radioactive Cytotoxicity assay (Promega, Madison, USA).
This assay quantitatively measures lactate dehydrogenase (LDH),
a cytosolic enzyme that is released upon cell lysis. Released LDH
in culture supernatant is measured with a 30-minute coupled
enzymatic assay, which results in the conversion of a tetrazolium
salt (INT) into a red formazan product. The amount of colour is
proportional to the number of lysed cells. Wavelength absorbance
data was collected using a multi-well scanning spectrophoto-
meter (ELISA reader). The percentage of specific cytotoxicity
was calculated according to the formula: % specific lysis=
[(Experimental-Effector Spontaneous-Target Spontaneous)/(Tar-
get Maximum-Target Spontaneous)] 6100.
Cytometric Bead Array
Supernatants from the different samples were collected after
performing the cytotoxicity assays. These were used for measuring
IFN-c release from the activated HER-2 specific CTLs and
control lymphocytes in the co-culture/cytotoxicity experiments as
described above. The procedure was followed as described
previously [30], following the manufacturer’s instruction and
samples were examined in triplicate for each condition.
TAP-1, TAP-2 and Tapasin expression in EAC cell lines and
EAC patient biopsies
To evaluate the status of three of the most important
components of the APM, namely, TAP-1, TAP-2 and Tapasin,
RT-PCR, ICC and IHC were performed on OE33, OE19 and
SW620 cell lines and on 16 EAC patient biopsies.
RNA from cell lines was isolated by using the Qiagen RNA
isolation Kit following manufacturer’s instructions (QIAGEN
Benelux B.V., The Netherlands) and preserved at 280uC until
use. RNA from the EAC patient biopsy specimens was isolated
performing the TRiZol Isolation method as described previously
[26]. Isolation was performed using the manufacturer’s
instructions.
Specific primers used for TAP-1, TAP-2 and Tapasin RT-PCR
were as follows: TAP-1 fw: AGTGGGAATCCTCTACATTG-
GTG; rv: TTGGGTAGGCAAAGGAGACA. TAP-2 fw: CTCGT-
TGCCGCCTTCTTCT; rv: AGTTCAGCTCCCCTGTCTTA-
GTC. Tapasin fw: CCACCATACACCTGCCATACC; rv: CCCA-
GTGCCTTGAAGAGCC [31]. The PCR program settings were as
follows: 5995u,3 5 6(1995u,1 958u,2 972u)1 0 972u.
IHC and ICC for the three proteins were performed both on cell
lines and EAC patient material as described above, using specific
antibodies for TAP-1 (Abcam, Cambridge, UK), TAP-2 (AMS
Biotechnology, Milton Park, Milton, UK) and Tapasin (Abcam,
Cambridge, UK) at dilutions of 1:50, 1:50 and 1:100 respectively.
IFN-c treatment and incubation with IFN- c producing
HER-2 specific CTLs
OE19 cell line was treated for 24, 48 and 72 hours with 5,
10 and 20 ng of IFN-c (Roche, The Netherlands). Subse-
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12424Figure 1. HER-2 status in EAC cell lines. HER-2 status in the EAC cell lines shows that OE33 and OE19 are characterized by high HER-2 gene
amplification, whereas SW620 exhibits polysomy of chromosome 17 only (A). On protein level, OE33 and OE19 both overexpress HER-2. The SW620
cell line does not over-express HER-2 (B). HLA-A2 status in OE33, OE19 and SW620 cell lines (violet=HLA-A2 expression; green=isotype control, C).
doi:10.1371/journal.pone.0012424.g001
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Qiagen RNA isolation kit, as described above, and RT-PCR
was performed to evaluate TAP-2 expression before and after
IFN-c treatment. OE19 cells either treated or not with IFN-c
were analyzed by FACS for measuring the expression of
HLA-A2.
To study re-expression of TAP-2 under more physiological
conditions, the OE19 cell line was also incubated for 48 hours
with HER-2 specific IFN-c producing CTLs. Restoration of TAP-
2 expression was monitored by ICC by using a specific antibody
for TAP-2 (AMS Biotechnology, Milton Park, Milton, UK). The
staining procedure was performed as described above. IFN-c
production by CTLs was measured by performing a CBA assay as
described above.
TAP-2 RNA interference in OE33
The OE33 cell line was seeded at a density of 2.5610
5 cells/
well in 24 well plates before transfection. Cells were left
overnight at 37uC for attachment; subsequently, culture media
was replaced with 1 ml antibiotic-free media 2 h before
transfection. Cells were placed in a transfection mixture
containing 400 ml of antibiotic-free media (Opti-Mem without
antibiotics) and 100 ml of transfection mixture, prepared with
8 ml siRNA against TAP-2 (TAP2 siRNA, Santa Cruz Biotech-
nology, 10 mM) or 3 ml of scrambled RNA diluted in 42 mlO p t i -
Mem with 0,5% serum (and 47 ml, respectively), mixed with 2 ml
DharmaFECT siRNA Transfection Reagent 1 (Dharmacon
RNA technology, Perbio Science, Nederland) diluted in 48 ml
Opti-Mem. Media was changed after 24 h and replaced with
normal culture medium (RPMI 1640) with 10% FCS. After
48 hours, cells were washed with PBS and harvested in Laemmly
sample buffer. The lysates were used to load 30 mlo fe a c h
sample per/lane, resolved by polyacrylamide gel electrophoresis
and probed by Western blotting using primary antibodies
specific against human TAP-2 (AMS Biotechnology, Milton
Park, Milton, UK), and b-actin (Santa Cruz) and a chemilumi-
nescent detection system (Roche, The Netherlands). The cells,
which displayed down-regulation of TAP-2, where subsequently
used in the cytotoxicity assay (see experimental procedure
above). The down-regulation of TAP-2 in OE33 was also
analyzed by ICC (procedure see above).
Statistics
To evaluate statistical differences between groups, Student’s t
test and Anova followed by Bonferroni post test for multiple
comparisons were used. Statistically significant difference was
considered at p,0.05.
Results
HER-2 expression and gene amplification in EAC cell lines
Determination of the HER-2 status in the OE33, OE19 EAC
cell lines and SW620 by DNA FISH revealed that OE33 and
OE19 are characterized by a high HER-2 amplification as
compared to SW620 that only showed polysomy of chromosome
17 (Fig.1A, Table 1). This was confirmed on the protein levels by
ICC, which showed a strong overexpression of HER-2 in OE33, a
weaker expression in OE19, whereas SW620 (control) showed no
staining (Fig.1B). The results on HER-2 expression observed by
ICC were further confirmed by FACS analysis (data not shown).
The HLA-A2 status of the three cell lines used was determined by
FACS analysis and resulted to be positive in all the three cell lines
(Fig. 1C, supplementary fig. S3).
Trastuzumab inhibits growth, but does not increase
apoptosis, in HER-2 overexpressing EAC cell lines
To evaluate the potential inhibitory activity of trastuzumab on
the HER-2 overexpressing cell lines, OE33, OE19 and the non
HER-2 overexpressing SW620 were treated with different
concentrations of trastuzumab for 24 and 72 hours. Hereafter,
MTT assays were performed to measure the growth inhibitory
effect of trastuzumab and cells were stained for Annexin V and
7aad to assess the level of apoptosis. Cells, which were not treated
with trastuzumab, showed a basal cell viability of on average
0.2160.02SEM for OE33 and on average 0.3460.02SEM for
OE19. Incubations for 24 and 72 hours with trastuzumab already
showed significant reductions in cell growth in OE33 and OE19 at
a dosage of 2.5 mg of trastuzumab (Paired T-test, p,0.05).
Increasing the dosage however, did not further affect cell viability
in OE33, but did decrease cell growth in OE19 (Fig.2A, B). In
SW620, a HER-2 negative colon cell line, no differences were
observed in cell viability for any incubation time using different
concentrations of trastuzumab (Fig.2C).
Annexin V and 7aad stainings performed to assess the apoptosis
level induced in trastuzumab treated EAC cell lines, showed no
significant increase in apoptosis as compared to non-treated cells
(Fig.2D). Violet areas indicate the population of treated cells, green
lines indicate the population of non treated cells, and purple dotted
lines indicate the population stained with the isotype control for
the Annexin V antibody.
Mixed Leukocyte Reaction (MLR) with HER-2 specific CTLs
FACS analysis performed using the HER-2 specific antibody,
confirmed that 24 hours after electroporation, HER-2 was
successfully expressed by the HER-2 RNA loaded DCs. At day
eight of the maturation process the mature DCs were still able to
present HER-2 antigens, as demonstrated by a significantly higher
MFI of 16086448SEM as compared to the control isotype
antibody and mock electroporated cells (MFI=167670 and




1 51 male EAC G2T3N1M1b
2 75 male EAC T3N0
3 50 male EAC T1N0
4 71 male EAC T3N1
5 53 male EAC T1N0M0
6 73 male EAC T3N0M0
7 80 male EAC T3N0M0
8 76 female EAC T1N0
9 58 male EAC T1N0
10 68 male EAC T4N1
11 76 female EAC T1N0
12 60 male EAC T1N0M0
13 82 male EAC T3N1M0
14 85 male EAC T3N1
15 78 male EAC T3/4N1
16 80 male EAC T1N0
17 77 male EAC T3N1M0
doi:10.1371/journal.pone.0012424.t001
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MLR, lymphocytes, which were stimulated by HER-2 loaded DCs
showed a significantly higher proliferation rate (Mean 24096
809SEM) as compared to the lymphocytes stimulated by mock-
electroporated DCs (Mean 7026131SEM, Paired T-test, p,0.05,
Fig.3B). The resulting anti HER-2 specific CTL population and
control CTL population (lymphocytes stimulated with mock
transfected DC) were subsequently used for the cytotoxicity assays.
IFN-c release by CTLs after cytotoxicity assay
After four hours of incubation for the cytotoxicity assay, the
supernatant obtained from the co-cultures of CTLs and the EAC
cell line OE33 either treated or not treated with trastuzumab was
collected and used to measure the IFN-c release by the CTLs
performing CBA. Production of IFN-c was significantly higher
when CTLs were co-incubated with OE33 without trastuzumab
pre-treatment, 324.8 pg/ml 6147.5SEM, as compared to the
basal IFN- c levels, 71.17 pg/ml671.7SEM, T-test, p,0.05
(Fig. 3C). In case OE33 cells were pre-treated with trastuzumab,
the production of IFN-c from the CTLs was significantly higher as
compared to the CTLs’ basal level of IFN-c production, 599.6 pg/
ml6197.9SEM (T-test, p,0.05). These results correlated with the
lytic activity as observed in the cytotoxicity assays.
Trastuzumab sensitizes OE33 but not OE19 to HER-2
specific CTL lysis
The cytolytic effects of different CTL populations on trastuzu-
mab treated and non treated EAC cell lines were studied. The
overall percentage of lysis induced by the HER-2 specific CTLs on
the HER-2 overexpressing EAC cell line OE33 was
14.4%67.1SEM, while the effect obtained with (control) aspecific
CTLs was 1%60.7SEM. After pre-treatment of the cell lines with
trastuzumab the lysis of the OE33 cell line increased to
36,8%611.8SEM, while the effect induced by aspecific CTLs
was 2.462.4SEM (Fig.4A and D, n=6). Under these different
conditions a mean cytotoxicity level of 2.261.1SEM was
measured for the OE19 cells (Fig.4B). Thus there was hardly
any cytolytic effect induced by the HER-2 specific CTLs or any
sensitizing effect of the trastuzumab pre-treatment observed on the
HER-2 over-expressing OE19 cells. As expected, SW620, which
Figure 2. The biological activity of trastuzumab on EAC cell lines. The HER-2 positive EAC cell lines treated with increasing concentrations of
trastuzumab for 24 and 72 hours, progressively show decreased cell viability in both OE33 and OE19 (A and B). SW620 (HER-2 negative colon cell line)
shows no sensitivity to trastuzumab (C) (Data are means 6 SD of six experimental points from two independent experiments). Apoptosis levels as
measured in EAC cell lines treated for 48 hours with 10 mg of trastuzumab does not show any difference between treated and not treated cells (Violet
area D= trastuzumab treated cells, Green line D= not treated cells, dotted line D= isotype control).
doi:10.1371/journal.pone.0012424.g002
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anti HER-2 specific CTLs with or without trastuzumab pre-
treatment (mean cytotoxicity in all the samples=1261.5SEM,
Fig.4C). In the control experiments, lymphocytes stimulated by
mock-transfected DCs, did not exhibit a cytotoxic effect on OE33,
either treated or not with trastuzumab (Fig. 4D).
IFN-c restores the HER-2 specific CTL lysis of OE19
Upon IFN-c treatment, the cytotoxic capacity of the HER-2
specific CTLs towards OE19 cell line was restored and increased
from 1.661.05 to 5.361.7SEM (Fig. 4C, one way Anova,
Bonferroni post test, p=0,003). With IFN-c treatment the
sensitizing effect of trastuzumab was as well restored. Simulta-
neous treatment with IFN-c and trastuzumab further increased the
mean cytotoxicity to 31.169.9SEM (Fig. 4B, One way Anova,
Bonferroni post test, p,0,05).
Inhibition of TAP-2 expression in OE33 reduces the
synergistic cytotoxic effect of trastuzumab and HER-2
specific CTLs
In order to further confirm that the synergistic cytotoxic effect
induced by simultaneous treatment of trastuzumab and HER-2
specific CTLs is dependent on TAP-2, we inhibited the expression of
TAP-2 in OE33 cell line by siRNA. We subsequently performed a
cytotoxicity assay on these cells, with or without Trastuzumab pre-
treatment. First we showed by ICC and Western blot that inhibition of
TAP-2 expression was successfully obtained on the TAP-2 siRNA
treated cells (Fig. 4E and supplementary fig. S6). By incubating these
TAP-2 deficient cells with HER-2 specific CTLs and trastuzumab, we
could observe that the CTL induced cytotoxicity in both trastuzumab
treated and not treated cells is decreased as compared to cells in which
the TAP-2 was not inhibited, and the % of lysis was on average
25,862,6 for the untreated cells, and 218,668,7 (n=2) (Fig. 4A).
TAP-1, 2 and Tapasin expression in EAC cell lines and EAC
patient material
To investigate the reason accounting for the deficient cytotoxic
response observed on OE19, expression of three important
components of the APM, TAP-1, TAP-2 and Tapasin, was
determined by RT-PCR, ICC and IHC in the EAC cell lines and
EAC patient material. In all three cell lines at RNA level, there
was normal expression of TAP-1 and Tapasin, while TAP-2
expression was absent in OE19 but positive in OE33 and SW620
(Fig.5A). ICC supported the RT-PCR results (see supplementary
fig. S7) and showed low expression of the TAP-2 protein in OE19
(see Fig. 5E). To look at the status of TAP-2 in patient material,
RT-PCR was performed on RNA isolated from 16 EAC biopsies,
and IHC was performed on correlating biopsies of the 16 EAC
patients. In 70% of the patients there was either a complete or a
Figure 3. Detection of HER-2 epitopes and HER-2 specific CTLs. Monocytes from HLA2A2+ donors were electroporated with IVT HER-2 RNA.
FACS analysis shows that after 24 hours and 8 days, HER-2 epitopes were specifically expressed in electroporated cells, while cells stained with an
isotype control and secondary antibody alone were virtually negative (Paired T-test, p,0.05, A, figures are representative of three independent
experiments). MLR of lymphocytes with either HER-2 electroporated DCs, or DCs, which underwent the electroporation (mock) procedure without
HER-2, shows that HER-2 electroporated DCs were able to induce significantly higher T-cell proliferation, as compared to the mock electroporated
DCs (Paired T-test, p,0.05, B, n=2). IFN-c release by CTLs incubated with HER-2 overexpressing OE33 cell line was significantly higher as compared to
CTLs alone (T-test, p,0.05). The release increased in case OE33 was pre-treated with trastuzumab (T-test, p,0.05, C, n=3).
doi:10.1371/journal.pone.0012424.g003
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protein level (Fig. 5B and C). RT-PCR and IHC was performed
on EAC biopsies to check as well the expression of TAP-1 and
Tapasin. In 70% of the biopsies specimens we found down-
regulation and/or complete lack of TAP-1 expression, and in 40%
down-regulation and/or lack of expression of Tapasin (see
supplementary fig. S1 and S2).
IFN-c and IFN-c producing CTLs restore TAP-2 expression
in OE19
To establish whether the TAP-2 deficiency displayed by OE19
is due to a transient down-regulation, OE19 was treated at several
time points with different concentrations of IFN-c: after 24 hours
it was already possible to observe an up-regulation of TAP-2 in
OE19, which notably increased after 48 hours (Fig. 5D).
Since the anti HER-2 CTL populations as raised by HER-2
RNA loaded DCs have the potential to produce high levels of INF-
c (see supplementary fig. S5), we incubated OE19 cells with these
specific CTLs for 48 hours. After a prolonged incubation of
24 hours with the IFN-c producing HER-2 specific CTLs, we
were able to observe a restored TAP-2 expression, as shown by
ICC analysis (Fig. 5E). FACS analysis performed on OE19 cells
either treated or not with IFN-c, showed that the HLA-A2
expression increased significantly in the cells which were treated
Figure 4. The sensitizing effect of trastuzumab. The cytotoxic capacity of HER-2 specific CTL populations was tested on the HER-2 positive EAC
cell lines pre-treated with trastuzumab. Results show that trastuzumab pre-treatment significantly enhances the sensitivity of OE33 cells to the HER-2
CTL lysis activity (A). This effect is not observed in OE19 cells, despite that this cell line does express HER-2 (B). SW620, which is HLA-A2 positive, but
HER-2 negative as expected does not show any sensitivity to trastuzumab treatment (C). Data are means 6 SEM of three experimental points from six
independent experiments. Simultaneous treatment of OE19 with IFN-c and trastuzumab restored the cytotoxicity effect induced by HER-2 specific
CTLs (C). Incubating OE33 cells with non-specific T cell population did not show any enhanced cytotoxic effect (D). SiRNA mediated inhibition of TAP-
2 expression in OE33 was successfully obtained as seen by ICC (E). Silencing of TAP-2 in OE33 with siRNA results in a significantly decreased CTL
response of these cells independent of pre-treatment with trastuzumab as compared to OE33 which were not transfected with siRNA for TAP-2 (A).
doi:10.1371/journal.pone.0012424.g004
APM Deficiency in EAC
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12424with IFN-c (MFI=45616 versus 158629, Fig. 5F and G and
supplementary fig. S3, n=2).
Discussion
The present report contains several important findings regard-
ing the underlying mechanism of action of the antibody
trastuzumab on HER-2 overexpressing EAC. Moreover, it proves
that an intact Antigen Processing Machinery (APM) in these
cancer cells is of pivotal importance for an optimal effect of
trastuzumab and for T-cell mediated immunotherapies. It is well
known that deficiencies in the expression of APM components can
hinder or entirely abolish anticancer immune-responses by
preventing proper CTL-induced cell lysis as a consequence of a
reduced level of MHC-Class I antigen presentation [32,33,34]. In
this regard, the sensitization to tumor cell lysis by MHC-Class I
restricted CTLs promoted by trastuzumab is dependent on a
proper APM function. For the above mentioned effect, it has
previously been shown that trastuzumab, by binding the HER-2
receptor, increases internalization and degradation of the latter,
Figure 5. APM status in EAC cell lines and patient biopsies and re-induction of TAP-2 by IFN-c and INF-c producing CTLs. TAP-1, TAP-
2 and Tapasin expression at RNA and protein level were detected by RT-PCR and IHC/ICC, respectively. TAP-1 and Tapasin are normally expressed in
OE19, while expression of TAP-2 is absent (A). RT-PCR shows that TAP-2 expression is lost or down-regulated in 70% of the tumor biopsies of EAC
patients (B). IHC on EAC biopsies of the same patients supports the RT-PCR results (C). RT-PCR shows re-induction of TAP-2 in OE19 after time course
incubations with 5, 10 or 20 ng of IFN-c (D). Co-incubation of OE19 with INF-c producing CTLs for 48 hours also restores TAP-2 expression (E). OE19
cells treated with IFN- c displays a significantly increased HLA-A2 expression as compared to not treated cells (MFI=45616 versus 158629, F and G).
doi:10.1371/journal.pone.0012424.g005
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available for loading to MHC class I [24,25]. Previously, Kono et
al, performed several studies to determine the exact mechanism of
trastuzumab, and they demonstrated that DCs pulsed with HER-
2/neu-derived peptides can induce specific T-cell responses in
patients with gastric cancer when these are pre-treated with
trastuzumab [12]. The same group demonstrated that trastuzu-
mab is able to induce a cytolytic response against HER-2–
expressing esophageal Squamous Cell Carcinoma (SCC) [35]. In
addition, recent studies demonstrated that HER-2 specific CTLs,
generated from HLA-A2 positive patients with HER-2 positive
breast cancer, can lyse HER-2 positive SKOV3tA2 breast cancer
cells in a HLA-A2 restricted manner [25]. These results suggest
that HER-2 specific CTLs can induce lysis of trastuzumab
sensitized HER-2-overexpressing tumors in a MHC-Class I
restricted manner [24].
In our study, we examined the HER-2 status of several EAC cell
lines and showed that OE33 and OE19 are characterized by high
levels of HER-2 gene amplification, confirming previous findings
[9], whereas SW620, a HLA-A2 positive colon cancer cell line
taken as control, is characterized by only polysomy of chromo-
some 17. These results correlated with the protein expression
levels as seen by ICC. As expected trastuzumab significantly
reduce cell viability and proliferation in OE33 and OE19 as
compared to not treated samples, whereas SW620 is not affected
by trastuzumab. In contrast, we found that trastuzumab treatment
does not result in an increase in apoptosis of OE33 and OE19,
confirming prior observations [24]. To find out whether
trastuzumab is able to induce sensitization of the HER-2 positive
EAC cell lines to HER-2 specific CTLs induced lysis, we co-
cultured HER-2 specific CTLs with EAC cells treated or not with
trastuzumab, and we found that treatment with trastuzumab
significantly sensitized the HER-2 overexpressing EAC cell line
OE33 to HER-2 specific MHC-Class I restricted CTL lysis. Yet,
to our surprise, this effect was not observed for the other HER-2
overexpressing cell line OE19. Since CTL mediated cytotoxicity is
dependent on presentation of antigens through an intact APM, we
investigated the status of the APM in the EAC cell lines and EAC
patient biopsy specimens. Amongst the APM components, the
Transporter associated with Antigen Processing 1 and 2 (TAP-1
and 2) polymorphisms and mutations are associated with hindered
anticancer responses and poor patient prognosis [36]. TAP-1 and
TAP-2 down-regulation in general will lead to a reduced efficiency
in antigen presentation and immune-responses [37] and is
considered as an important mechanism of cancer immune-escape
[38]. We found normal expression levels of TAP-1 and Tapasin
but significant down-regulation of TAP-2 in OE19. Moreover,
absent or decreased expression of TAP-2 protein was seen in 70%
of the EAC cases. It is well known that components of the APM
feature an IFN-c response element on their genes, therefore IFN-c
is the most potent up-regulator of TAP-1 and TAP-2 expression in
case these protein are de-regulated, and not mutated [39]. By RT-
PCR and ICC we showed that IFN-c and co-incubation of OE19
with IFN-c producing anti-HER-2 CTLs efficiently restored TAP-
2 expression. Importantly, by performing FACS analysis we found
that expression of MHC-Class I molecules on OE19 is increased
upon treatment with IFN-c. Next we also showed that the HER-2
specific CTL induced cytotoxicity towards OE19 was restored
after treatment with IFN-c. Moreover, we observed that
simultaneous INF-c and trastuzumab treatment resulted in
significantly increased cell lysis of OE19 as compared to the
IFN-c treatment alone. Conversely, we demonstrated that this
mechanism of action of trastuzumab is dependent on a proper
TAP-2 expression, since down-regulation of this APM component
by siRNA in OE33, resulted in an expected reduced CTL
cytotoxicity, but also abolished the synergistic effect of trastuzu-
mab and T-cells. Our observation that TAP-2 down-regulation is
frequently seen in EAC patients indicates that in a clinical setting
an impaired APM function could hamper patient response to
immunotherapy and the sensitizing effect of trastuzumab. An
important direction to solve this important issue would be to
combine trastuzumab with DC immunotherapy or IFN-c. DCs
may induce anti-HER-2 CTLs with the capacity of producing
high INF-c levels. Once these CTLs invade the tumor environ-
ment and target the tumor cells, INF-c release could re-establish
TAP-2 expression. In turn, trastuzumab would highly enhance
antigen presentation, which would sensitize the cells and target
them to CTL-induced tumor cell lysis. Finally, it is important to
note that NK cells might also be involved in the response of the
patient to trastuzumab as treatment of OE33 with trastuzumab
increases HER-2 positive PBMCs induced antibody-dependent
cell-mediated cytotoxicity (ADCC) on OE33 as compared to
untreated cells. Conversely, this phenomenon is not observed
when OE33 are incubated with PBMCs isolated from an HER-2
negative patient (supplementary fig. S4). These observations
confirm previous results obtained in gastric carcinoma and
esophageal squamous carcinoma from the group of Kono et al.
[13,22] where it was shown that trastuzumab act as an inducer of
the ADCC mechanism.
We conclude that a proper function of the APM is necessary for
both an effective CTL response and for inducing an optimal
immune response to trastuzumab. Of importance is the fact that
potent IFN-c producing CTLs by themselves may reinstate down
regulated TAP and facilitate cytotoxicity. In the future it would be
highly interesting to evaluate the APM status of patients who are
treated with trastuzumab or T cell-mediated immunotherapies
and to investigate whether this truly correlates with tumor
responsiveness and long term patient outcomes. Our data offers
convincing arguments for treating EAC patients carrying HER-2
overexpression with a combinatorial therapy consisting of
trastuzumab and IFN-c or anti-HER-2 directed T cell-mediated
immunotherapy.
Supporting Information
Figure S1 To evaluate the status of three of the most important
components of the APM, namely, TAP-1, TAP-2 and Tapasin,
RT-PCR, ICC and IHC were performed on OE33, OE19 and
SW620 cell lines and on 16 EAC patient biopsies. IHC for the
three proteins were performed EAC patient material using specific
antibodies for TAP-1, TAP-2 and Tapasin at dilutions of 1:50,
1:50 and 1:100 respectively. In this figures there are representative
examples of patients which resulted negative or positive to the
TAP-1 and the Tapasin staining.
Found at: doi:10.1371/journal.pone.0012424.s001 (1.08 MB TIF)
Figure S2 To evaluate the status of three of the most important
components of the APM, namely, TAP-1, TAP-2 and Tapasin,
RT-PCR was performed on 16 EAC patient biopsies. 70% of the
patients showed lack and/or down-regulation of the expression of
both TAP-1 and/or TAP-2, and a minority (6 out of 16) showed
lack or down-regulation of the expression of Tapasin.
Found at: doi:10.1371/journal.pone.0012424.s002 (0.54 MB TIF)
Figure S3 HLA-A2 status was checked by performing FACS
analysis of OE33 and OE19. Although both OE19 and OE33
resulted to be HLA-A2 positive, OE19 showed a significantly
lower expression of HLA-A2. After treatment with IFN-c, the level
of expression of HLA-A2 in OE19 significantly increased.
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Figure S4 PBMCs isolated either from HER-2 positive patients
and HER-2 negative patients were incubated with OE33 treated
or not treated with Trastuzumab and subsequently a cytotoxicity
assay was performed. It is possible to observe that PBMCs isolated
from HER-2 positive patients induced a significantly higher
cytotoxicity, probably due to antibody-dependent cell-mediated
cytotoxicity (ADCC) on OE33 as compared to untreated cells.
Conversely, this phenomenon is not observed when OE33 are
incubated with PBMCs isolated from an HER-2 negative patient.
Found at: doi:10.1371/journal.pone.0012424.s004 (1.69 MB TIF)
Figure S5 IFN-c production from the CTLs which were co-
incubated with OE19 in order to up-regulate TAP-2 expression
was checked by CBA and a significantly higher production was
detected from the CTLs incubated with HER-2 RNA transfected
DC as compared to T cells incubated with mock transfected DC.
Found at: doi:10.1371/journal.pone.0012424.s005 (0.75 MB TIF)
Figure S6 In order to inhibit TAP-2 expression, OE33 cell line
was transfected with a siRNA mixture targeting TAP-2. By
western blot and ICC we showed that TAP-2 expression was
successfully down-regulated in the cells which were transfected
with siRNA for TAP-2 as compared to those which were not
transfected.
Found at: doi:10.1371/journal.pone.0012424.s006 (0.07 MB TIF)
Figure S7 To evaluate the status of three of the most important
components of the APM, namely, TAP-1, TAP-2 and Tapasin,
ICC was performed on OE33 and OE19. In both the cells lines on
protein level there was normal expression of TAP-1 and Tapasin,
whereas TAP-2 expression was absent in OE19. These results
confirmed the RT-PCR data.
Found at: doi:10.1371/journal.pone.0012424.s007 (3.00 MB TIF)
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